Bringing the fundamentals into focus…
Back to Ascendis Pharma A/S
How Ascendis Pharma A/S stacks up
ASND · against 127 other Healthcare companies of similar size
Valuation
36/ 100
Near the bottom of its peers.
Ranked #108 of 128 · scores higher than 16% of peers
Bars: peers in each 10-point band of the valuation score12 peers with a valuation score of 30–39, including ASND · Click a bar to see the companies
Why valuation scores 36?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, which is weaker than most Healthcare peers.
- less operating profit (EBITDA) for the company's total value: weaker than 62% of peers. EBITDA yield: 1.8% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 62% of peers. Free cash flow yield: 2.3% vs peer median 0.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -1.7% vs peer median 1.5%
Metric by metric
Position: dot = ASND, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ASND | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 126 reported | 5.2% | 3.0% | 86% | 30% | |
| EBITDA yieldHigher is better · 129 reported | 1.8% | 5.2% | 25% | 50% | |
| Free cash flow yieldHigher is better · 83 reported | 2.3% | 3.1% | 38% | 20% | |
| Book yieldHigher is better · 125 reported | Not reported | 21.0% | — | — | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around ASND| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 2 | 10.4B USD | 96 | 64 | |
| 3 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 3 | 21.5B USD | 95 | 60 | |
| 5 | 11.6B USD | 94 | 58 | |
| 102 | 9.1B USD | 38 | 74 | |
| 105 | 14.87T KRW (≈$10.7B) | 37 | 76 | |
| 105 | 8.6B USD | 37 | 30 | |
| 105 | 10.1B USD | 37 | 61 | |
| 108 | 16.5B USD | 36 | 37 | |
| 109 | 8.8B USD | 33 | 50 | |
| 110 | 8.9B USD | 32 | 51 | |
| 111 | 10.1B EUR (≈$11.1B) | 29 | ||
| 112 | 10.2B USD | 8 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score